The American Heart Association’s 2024 Predicting Risk of Cardiovascular Disease Events equations can identify testicular cancer survivors at heightened risk for future cardiovascular events, according to a study led by researchers at Indiana University and Medical College of Wisconsin.
Testicular cancer survivors treated with four cycles of etoposide and cisplatin had significantly higher odds of renal impairment, hearing loss, and peripheral neuropathy compared with those treated with three cycles of bleomycin, etoposide, and cisplatin, according to a large, multi-center study. Nearly 41% of all survivors in the study showed some degree of at least mild renal dysfunction, which was strongly associated with cumulative cisplatin dose.
